LU90317I2 - Tacrolimus et ses sels et dérivés pharmaceutiquement acceptables - Google Patents

Tacrolimus et ses sels et dérivés pharmaceutiquement acceptables

Info

Publication number
LU90317I2
LU90317I2 LU90317C LU90317C LU90317I2 LU 90317 I2 LU90317 I2 LU 90317I2 LU 90317 C LU90317 C LU 90317C LU 90317 C LU90317 C LU 90317C LU 90317 I2 LU90317 I2 LU 90317I2
Authority
LU
Luxembourg
Prior art keywords
tacrolimus
derivatives
pharmaceutically acceptable
acceptable salts
diseases
Prior art date
Application number
LU90317C
Other languages
English (en)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848430455A external-priority patent/GB8430455D0/en
Priority claimed from GB858502869A external-priority patent/GB8502869D0/en
Priority claimed from GB858508420A external-priority patent/GB8508420D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of LU90317I2 publication Critical patent/LU90317I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C12R2001/55—Streptomyces hygroscopicus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/898—Streptomyces hygroscopicus
LU90317C 1984-12-03 1998-11-11 Tacrolimus et ses sels et dérivés pharmaceutiquement acceptables LU90317I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB848430455A GB8430455D0 (en) 1984-12-03 1984-12-03 Fr-900506 substance
GB858502869A GB8502869D0 (en) 1985-02-05 1985-02-05 Ws 7238 substances
GB858508420A GB8508420D0 (en) 1985-04-01 1985-04-01 Fr-900506 & fr-900525 substances

Publications (1)

Publication Number Publication Date
LU90317I2 true LU90317I2 (fr) 1999-01-11

Family

ID=27262535

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90317C LU90317I2 (fr) 1984-12-03 1998-11-11 Tacrolimus et ses sels et dérivés pharmaceutiquement acceptables

Country Status (24)

Country Link
US (15) US4894366A (fr)
EP (1) EP0184162B1 (fr)
JP (6) JPH0372483A (fr)
KR (5) KR930010704B1 (fr)
CN (1) CN1013687B (fr)
AT (1) ATE104984T1 (fr)
AU (1) AU592067B2 (fr)
CA (1) CA1338491C (fr)
CY (1) CY1912A (fr)
DE (2) DE19575026I2 (fr)
DK (1) DK169550B1 (fr)
ES (1) ES8705038A1 (fr)
FI (2) FI87803C (fr)
GR (1) GR852904B (fr)
HK (1) HK18596A (fr)
HU (1) HU195250B (fr)
IE (1) IE62865B1 (fr)
IL (2) IL92345A (fr)
LU (1) LU90317I2 (fr)
MX (1) MX9202943A (fr)
NL (1) NL960023I2 (fr)
NO (1) NO168372C (fr)
NZ (1) NZ214407A (fr)
PT (1) PT81589B (fr)

Families Citing this family (311)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5266692A (en) * 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
ATE98700T1 (de) * 1987-06-05 1994-01-15 Fujisawa Pharmaceutical Co Anti-fr-900506-stoffe-antikoerper und hoechstempfindliches enzym-immunoassay-verfahren.
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
DE3838035C2 (de) * 1987-11-09 1994-03-24 Sandoz Ag Neue Verwendung von 11,28-dioxa-4-azatricyclo[22.3.1.O·4··,··9·]octacos-18-en-Derivaten
AT400808B (de) * 1987-11-09 1996-03-25 Sandoz Ag Verwendung von tricyclischen verbindungen zur herstellung von topischen arzneimitteln
DE3844904C2 (de) * 1987-11-09 1997-01-30 Sandoz Ag Neue Verwendung von 11,28-Dioxa-4-azatricyclo-[22.3.1.0·4·,·9·]octacos-18-en-Derivaten
CH677448A5 (fr) * 1987-11-09 1991-05-31 Sandoz Ag
US5366971A (en) * 1987-11-09 1994-11-22 Sandoz Ltd. Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
GB8728820D0 (en) * 1987-12-09 1988-01-27 Fisons Plc Compounds
EP0346427B1 (fr) * 1987-12-09 1995-03-29 FISONS plc Composes macrocycliques
AT407957B (de) * 1987-12-17 2001-07-25 Novartis Erfind Verwalt Gmbh Neue verwendung von 11,28-dioxa-4-azatricyclo- (22.3.1.04,9)octacos-18-en-derivaten und sie enthaltende pharmazeutische zubereitungen
EP0323865A1 (fr) * 1988-01-07 1989-07-12 Merck & Co. Inc. Agent immunopresseur
US4981792A (en) * 1988-06-29 1991-01-01 Merck & Co., Inc. Immunosuppressant compound
DE68921934T2 (de) * 1988-06-29 1995-10-19 Merck & Co Inc Immunsuppressives Agens.
US5290772A (en) * 1988-06-29 1994-03-01 Merck & Co., Inc. Immunosuppressant agent
ATE131536T1 (de) * 1988-08-01 1995-12-15 Fujisawa Pharmaceutical Co Fr-901154- und fr-901155-derivate, verfahren zu ihrer herstellung
US5202258A (en) * 1988-08-05 1993-04-13 Merck & Co., Inc. Immunosuppressant-producing culture
EP0356399A3 (fr) * 1988-08-26 1991-03-20 Sandoz Ag Dérivés substitués du 4-azatricyclo (22.3.1.04.9) octacos-18-ène, leur préparation et les compositions pharmaceutiques les contenant
EP0358508A3 (fr) * 1988-09-08 1991-03-20 Merck & Co. Inc. Composé immunosuppreseur
EP0364031B1 (fr) * 1988-10-12 1992-12-23 Merck & Co. Inc. Procédé pour le réarrangement du composé FK-506 utilisant un hydroxide comme médiateur
US4980466A (en) * 1988-10-12 1990-12-25 Merck & Co., Inc. Hydroxide mediated FK-506 rearrangement product
CA1316916C (fr) * 1988-10-12 1993-04-27 David Askin Produit du rearrangement du fk-506 par l'entremise d'un hydroxyde
GB2225576B (en) * 1988-11-29 1992-07-01 Sandoz Ltd Substituted azatricyclo derivatives and metabolites,their preparation and pharmaceutical compositions containing them
EP0378320A3 (fr) * 1989-01-13 1990-11-28 Merck & Co. Inc. Produit de transformation microbienne
US4975372A (en) * 1989-01-13 1990-12-04 Merck & Co., Inc. Microbial transformation product of L-683,590
EP0378317A3 (fr) * 1989-01-13 1990-11-28 Merck & Co. Inc. Produit de transformation microbienne L-679,934
US5268370A (en) * 1989-01-13 1993-12-07 Merck & Co., Inc. Microbial transformation product of L-679,934
EP0388152B1 (fr) * 1989-03-15 1994-10-12 Merck & Co. Inc. Procédé de préparation d'un agent immunosuppressif (demethimmunomycine) mettant en oeuvre une souche mutante d'un microorganisme
EP0388153B1 (fr) * 1989-03-15 1994-12-28 Merck & Co. Inc. Agent immunosuppressif
US5272068A (en) * 1989-03-15 1993-12-21 Merck & Co., Inc. Process for producing immunosuppressant agent L-683942 by fermentation
US5155228A (en) * 1989-03-23 1992-10-13 Merck & Co., Inc. FK-506 C10-C18 process intermediates
US4940797A (en) * 1989-03-23 1990-07-10 Merck & Co., Inc. Process for synthesis of FK-506 C10-C18 intermediates
US5057608A (en) * 1989-04-21 1991-10-15 Merck & Co., Inc. Immunoregulants, immunosuppressants, process to make ring expanded macrolide related to FK-506/FK-520
CA2014841A1 (fr) * 1989-04-21 1990-10-21 Byron H. Arison Macrolides ayant une acticite immunosuppressive
US5068323A (en) * 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
EP0396400A1 (fr) * 1989-05-05 1990-11-07 Merck & Co. Inc. Produit microbien de transformation
US5270187A (en) * 1989-05-05 1993-12-14 Merck & Co., Inc. Microbial transformation product
US4987139A (en) * 1989-05-05 1991-01-22 Merck & Co., Inc. FK-520 microbial transformation product
IE64214B1 (en) * 1989-06-06 1995-07-26 Fujisawa Pharmaceutical Co Macrolides for the treatment of reversible obstructive airways diseases
CA2018710A1 (fr) * 1989-06-13 1990-12-13 Shieh-Shung T. Chen L-683590, produits de transformation microbienne
US5138052A (en) * 1989-06-13 1992-08-11 Merck & Co., Inc. L-683,590 microbial transformation product
EP0402931A1 (fr) * 1989-06-14 1990-12-19 Sandoz Ltd. Composés tricycliques contenant des hétéro-atomes
US5164525A (en) * 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
US5235066A (en) * 1989-06-30 1993-08-10 Merck & Co., Inc. FK-506 type macrolide intermediate
JPH05504944A (ja) * 1989-08-18 1993-07-29 藤沢薬品工業株式会社 巨大環式化合物
EP0413532A3 (en) * 1989-08-18 1991-05-15 Fisons Plc Macrocyclic compounds
US5011943A (en) * 1989-08-28 1991-04-30 Merck Frosst Canada, Inc. FK-506 C10 -C24 process intermediates
GR1001225B (el) * 1989-09-14 1993-06-30 Fisons Plc Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους.
US5215995A (en) * 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
IE904050A1 (en) * 1989-11-13 1991-05-22 Merck & Co Inc Aminomacrolides and derivatives having immunosuppressive¹activity
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
GB8925797D0 (en) * 1989-11-15 1990-01-04 Fisons Plc Compositions
EP0444829A3 (en) * 1990-02-27 1992-06-03 Fisons Plc Immunosuppressive compounds
US5064835A (en) * 1990-03-01 1991-11-12 Merck & Co., Inc. Hydroxymacrolide derivatives having immunosuppressive activity
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
WO1991013899A1 (fr) * 1990-03-12 1991-09-19 Fujisawa Pharmaceutical Co., Ltd. Composes tricyclo
US5296489A (en) * 1990-03-13 1994-03-22 Fisons Immunosuppressive macrocyclic compounds
JPH05505798A (ja) * 1990-03-13 1993-08-26 フアイソンズ・ピーエルシー 免疫抑制マクロ環状化合物
CA2040551A1 (fr) * 1990-04-30 1991-10-31 Mark T. Goulet Derives de desoxymacrolide ayant une activite immunosuppressive
WO1991017754A1 (fr) * 1990-05-11 1991-11-28 Fujisawa Pharmaceutical Co., Ltd. Procedes servant a traiter et a prevenir une inflammation des muqueuses et des vaisseaux sanguins en utilisant du fk 506 et des composes connexes
WO1991019495A1 (fr) * 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. Utilisation d'un compose de macrolide tel que le fk 506 pour fabriquer un medicament destine a traiter la purpura thrombocytopenique idiopathique et la maladie de basedow
US5643901A (en) * 1990-06-11 1997-07-01 Fujisawa Pharmaceutical Co., Ltd. Medicament for treating idiopathic thrombocytopenic purpura
US5342935A (en) * 1990-06-25 1994-08-30 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
CA2044846A1 (fr) * 1990-06-25 1991-12-26 Thomas R. Beattie Antagonistes de macrolides immunosuppresseurs
US5210030A (en) * 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
US5190950A (en) * 1990-06-25 1993-03-02 Merck & Co., Inc. Antagonists of immunosuppressive macrolides
GB9014136D0 (en) * 1990-06-25 1990-08-15 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
GB9014681D0 (en) * 1990-07-02 1990-08-22 Fujisawa Pharmaceutical Co Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
MY110418A (en) * 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
EP0466365A3 (en) * 1990-07-03 1992-04-15 Merck & Co. Inc. Novel immunosuppressant fermentation products of a microorganism
GB2245891A (en) * 1990-07-09 1992-01-15 Fujisawa Pharmaceutical Co Tricyclo compounds
GB2246350A (en) * 1990-07-23 1992-01-29 Fujisawa Pharmaceutical Co Tricyclo compounds
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
JPH06500102A (ja) * 1990-08-18 1994-01-06 フアイソンズ・ピーエルシー マクロ環状化合物
GB2247620A (en) * 1990-09-07 1992-03-11 Fujisawa Pharmaceutical Co The use of macrolide compounds for cytomegalovirus infection
CA2051872A1 (fr) * 1990-09-24 1992-03-25 Kevin M. Byrne Procede de biosynthese dirigee de la prolyl-immunomycine
GB2248184A (en) * 1990-09-28 1992-04-01 Fujisawa Pharmaceutical Co New use of macrolide compounds for active oxygen-mediated diseases
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5348966A (en) * 1990-10-24 1994-09-20 Fujisawa Pharmaceutical Co., Ltd. Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds
CA2054128A1 (fr) * 1990-10-29 1992-04-30 Kevin M. Byrne Procede de production d'analogues de l'immunomycine
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (fr) * 1990-11-08 1992-05-09 Sotoo Asakura Composition suspensible et procede de fabrication
GB2249787A (en) * 1990-11-19 1992-05-20 Fujisawa Pharmaceutical Co Lactone compounds
GB9027471D0 (en) * 1990-12-19 1991-02-06 Fujisawa Pharmaceutical Co Novel compound
US5116756A (en) * 1991-01-28 1992-05-26 Merck & Co., Inc. Process for producing FK-506
US5194378A (en) * 1991-01-28 1993-03-16 Merck & Co., Inc. Process for producing fk-506
WO1992013862A1 (fr) * 1991-02-05 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Composes de lactone
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
WO1992019278A1 (fr) * 1991-04-26 1992-11-12 Kurume University Utilisation de composes macrolides pour les maladies des yeux
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5262533A (en) * 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
EP0528452A1 (fr) * 1991-06-19 1993-02-24 Merck & Co. Inc. Immunomycin produit par méthylation enzymatiques ou microbièles
US5225403A (en) * 1991-06-25 1993-07-06 Merck & Co., Inc. C-21 hydroxylated FK-506 antagonist
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5198358A (en) * 1991-08-28 1993-03-30 Merck & Co., Inc. Microorganism for producing C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5149701A (en) * 1991-08-01 1992-09-22 Merck & Co., Inc. C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5561228A (en) * 1991-09-05 1996-10-01 Abbott Laboratories Macrocyclic immunomodulators
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
ZA926812B (en) 1991-09-09 1993-04-28 Merck & Co Inc O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5252732A (en) * 1991-09-09 1993-10-12 Merck & Co., Inc. D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity
US5164495A (en) * 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
US5221625A (en) * 1992-01-10 1993-06-22 Merck & Co., Inc. Cyclcic FR-900520 microbial biotransformation agent
US5801144A (en) * 1992-01-28 1998-09-01 Karpas; Abraham Use of a compound for the manufacture of a medicament for the treatment of HIV infection
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
US5612316A (en) * 1992-03-02 1997-03-18 Pfizer Inc. Fluorosugar derivatives of macrolides
WO1993018050A1 (fr) * 1992-03-02 1993-09-16 Pfizer Inc. Derives de sucre de macrolides
EP0636136B1 (fr) * 1992-03-02 1997-10-29 Pfizer Inc. Derives de 2-aminosucres de macrolides
CA2131371A1 (fr) * 1992-03-02 1993-09-16 James R. Hauske Derives desosamines de macrolides utilises comme immunosuppresseurs et agents antifungiques
DK0562853T3 (da) 1992-03-27 1996-07-01 American Home Prod 29-Demethoxyrapamycin til fremkaldelse af immunsuppression
CA2091194A1 (fr) * 1992-04-08 1993-10-09 Richard D. Connell Derives 2-oxoethyliques utilises comme immunosuppresseurs
HUT66531A (en) * 1992-05-07 1994-12-28 Sandoz Ag Heteroatoms-containing tricyclic compounds, pharmaceutical prepns contg. them and process for producing them
AU4400593A (en) * 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5264355A (en) * 1992-07-02 1993-11-23 Merck & Co., Inc. Methlating enzyme from streptomyces MA6858
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5324644A (en) * 1992-07-28 1994-06-28 Merck & Co., Inc. Process for producing immunosuppressant agent
DE69331585T2 (de) * 1992-08-12 2002-08-08 Fujisawa Pharmaceutical Co Monoklonaler antikörper spezifisch für das fk-506-bindende protein, methode zur bestimmung des gehaltes an fk-506-bindendem protein in einer probe und reagenzsatz dafür
US5365948A (en) * 1992-08-21 1994-11-22 J & W Mcmichael Software Inc. Method for use in treating a patient with FK 506 to prevent an adverse immune response
US5268281A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5283183A (en) * 1992-09-28 1994-02-01 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5268282A (en) * 1992-09-28 1993-12-07 Merck & Co., Inc. Cyclic FR-900520 microbial biotransformation agent
US5290689A (en) * 1992-09-28 1994-03-01 Merck & Co., Inc. New cyclic FR-900520 microbial biotransformation agent
US5318895A (en) * 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
GB9227055D0 (en) * 1992-12-29 1993-02-24 Fujisawa Pharmaceutical Co New use
DE4300478C2 (de) * 1993-01-11 1998-05-20 Eos Electro Optical Syst Verfahren und Vorrichtung zum Herstellen eines dreidimensionalen Objekts
WO1994021254A1 (fr) * 1993-03-17 1994-09-29 Abbott Laboratories Immunomodulateurs macrocycliques substitues contenant des amines alicycliques
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5359060A (en) * 1993-07-06 1994-10-25 Pfizer, Inc. Phosponated derivatives of macrolides
CA2166892A1 (fr) * 1993-07-30 1995-02-09 Yat Sun Or Macrolactames actives, agents immunoregulateurs
GB2281294A (en) * 1993-08-23 1995-03-01 Fujisawa Pharmaceutical Co Process for producing half esters of the macrolide FK506
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
US5880280A (en) * 1994-06-15 1999-03-09 Merck & Co., Inc. Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
MX9702699A (es) 1994-10-26 1997-06-28 Novartis Ag Composiciones farmaceuticas.
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
US5616595A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
ATE254450T1 (de) 1995-09-19 2003-12-15 Fujisawa Pharmaceutical Co Aerosolzusammensetzungen
PT956034E (pt) 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
KR100244164B1 (ko) * 1997-07-15 2000-03-02 김용옥 수용성 고분자-타크로리무스 접합체 화합물 및 그의 제조 방법
US6562620B2 (en) * 1997-09-19 2003-05-13 Mcgill University Medium to promote islet cell survival
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20030129215A1 (en) 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US8257726B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8394398B2 (en) 1997-09-26 2013-03-12 Abbott Laboratories Methods of administering rapamycin analogs with anti-inflammatories using medical devices
US8057816B2 (en) 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7357942B2 (en) 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
JP2002503692A (ja) * 1998-02-23 2002-02-05 藤沢薬品工業株式会社 マクロライド系化合物の緑内障治療用途
AUPP223198A0 (en) * 1998-03-06 1998-04-02 Fujisawa Pharmaceutical Co., Ltd. New use
ES2219000T3 (es) 1998-03-26 2004-11-16 Fujisawa Pharmaceutical Co., Ltd. Preparacion de liberacion sostenida de un compuesto macrolido.
SK462001A3 (en) 1998-07-17 2002-02-05 Agouron Pharma Compounds, compositions, and methods for stimulating neuronal growth and elongation
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7455853B2 (en) 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
KR20010085877A (ko) 1998-10-02 2001-09-07 추후제출 폴리케타이드 합성 효소와 그 재조합 ｄｎａ 구성물
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
JP2002540211A (ja) * 1999-03-31 2002-11-26 アボット・ラボラトリーズ フォスフェート含有大環免疫調節薬
US6121257A (en) * 1999-03-31 2000-09-19 Abbott Laboratories Sulfamate containing macrocyclic immunomodulators
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
JP5127096B2 (ja) * 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) * 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
GB9917158D0 (en) * 1999-07-21 1999-09-22 Fujisawa Pharmaceutical Co New use
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US7018405B2 (en) 2000-12-22 2006-03-28 Avantec Vascular Corporation Intravascular delivery of methylprednisolone
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
ZA200406350B (en) 2002-02-13 2006-11-29 Teva Gyogyszergyar Reszveny Tarsasag Method for extracting a macrolide from biomatter
US7452692B2 (en) * 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
US7030129B2 (en) * 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
WO2004003214A1 (fr) * 2002-06-28 2004-01-08 Biocon Limited Fermentation a l'etat solide et production a ecoulement discontinu d'un immunosuppresseur
EP3175870A1 (fr) 2002-09-06 2017-06-07 Abbott Laboratories Dispositif médical doté d'un inhibiteur de l'hydratation
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
AU2003209664A1 (en) * 2003-02-10 2004-08-30 Biocon Limited Solid state fermentation and fed batch for the production of an immunosuppressant
DE04758730T1 (de) * 2003-03-31 2005-06-23 Biogal Gyogyszergyar Rt. Kristallisierung und Reinigung von Makroliden
US20060169199A1 (en) * 2003-03-31 2006-08-03 Vilmos Keri Crystallization and purification of macrolides
CN1819817A (zh) * 2003-07-09 2006-08-16 株式会社钟根堂 一种泰克利玛的固体分散体
ATE378345T1 (de) * 2003-07-24 2007-11-15 Teva Gyogyszergyar Zartkoeruee Verfahren zur aufreinigung von makroliden
EP1652550A1 (fr) * 2003-08-05 2006-05-03 Kaneka Corporation Stent a mettre en place in vivo
ATE531368T1 (de) 2003-08-29 2011-11-15 Veloxis Pharmaceuticals As Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung
BRPI0413927B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica compreendendo tacrolimus, forma de dosagem, uso da composição, e, método para a preparação da composição
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
DE602004018547D1 (de) * 2003-10-17 2009-01-29 Ranbaxy Lab Ltd Herstellung von tacrolimus (fk-506) unter verwendung neuer streptomyces-spezies
AU2004292445B2 (en) 2003-11-21 2010-02-04 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders
RU2317991C1 (ru) * 2003-12-05 2008-02-27 Байокон Лимитид Способ выделения и очистки макролидов
KR100485877B1 (ko) * 2003-12-30 2005-04-28 종근당바이오 주식회사 타크롤리무스를 생산하는 미생물 및 이를 이용한타크롤리무스의 대량 생산방법
US20050176080A1 (en) * 2004-02-10 2005-08-11 Vani Bodepudi Hapten, immunogens and derivatives of ascomycin useful for preparation of antibodies and immunoassays
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
ATE534424T1 (de) 2004-03-19 2011-12-15 Abbott Lab Mehrfache arzneiabgabe aus einem ballon und eine prothese
EP1756290B1 (fr) 2004-04-12 2016-05-04 Biocon Limited Streptomyces espece bicc 7522 et son utilisation pour la production de macrolides
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
JP2006014722A (ja) * 2004-06-02 2006-01-19 Keio Gijuku 遺伝子マーカー及びその利用
CA2571710A1 (fr) 2004-06-24 2006-11-02 Nicholas Valiante Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
WO2006080951A2 (fr) * 2004-07-01 2006-08-03 Yale University Materiaux polymeres charges de medicaments cibles a forte densite
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
CA2580127A1 (fr) * 2004-09-10 2006-03-23 Ivax Pharmaceuticals S.R.O. Procede pour isoler du tacrolimus cristallin
BRPI0515699A (pt) * 2004-09-10 2008-07-29 Ivax Pharmaceuticals Sro processo para isolamento de compostos de macrolido
GT200500282A (es) * 2004-10-12 2006-05-04 Heteroatomos conteniendo compuestos triciclicos.
ITMI20042098A1 (it) * 2004-11-03 2005-02-03 Antibioticos Spa Processo per la purificazione di tacrolimus
WO2006060614A1 (fr) * 2004-12-01 2006-06-08 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Procede de preparation du pimecrolimus
WO2006066063A1 (fr) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Formulations renfermant des nanoparticules de tacrolimus
JP2007523201A (ja) * 2004-12-22 2007-08-16 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ タクロリムスを精製する方法
CA2593019A1 (fr) * 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions et procedes concernant de nouveaux composes et leurs cibles
EP1833835A1 (fr) * 2005-01-05 2007-09-19 Teva Gyogyszergyar Zartkoruen Müködö R Szv Nytarsa Tacrolimus amorphe et sa preparation
ATE532064T1 (de) * 2005-01-13 2011-11-15 Univ Keio Genmarker und dessen verwendung
EP1877004A4 (fr) 2005-03-23 2012-01-25 Abbott Lab Compositions et procedes pour l'administration d'analogues de rapamycine au moyen de dispositifs medicaux pour une efficacite de longue duree
EP1868663B1 (fr) 2005-03-23 2011-11-16 Abbott Laboratories Distribution d'agents hautement lipophiles au moyen de dispositifs medicaux
EP1893218A4 (fr) 2005-06-01 2011-01-12 Univ Michigan Préparations de benzodiazépine non solvatées et méthodes
CN1876822B (zh) * 2005-06-06 2010-05-12 上海市农药研究所 他克莫司的产生菌株及生产方法
WO2007013017A1 (fr) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Processus de purification de macrolides
ITMI20051549A1 (it) * 2005-08-05 2007-02-06 Antibioticos Spa Purificazione del tacrolimus su supporti dimorigine vegetale
WO2007029082A2 (fr) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Procede de fermentation ameliore pour la preparation d'ascomycine
US20080318289A1 (en) * 2005-10-05 2008-12-25 Parveen Kumar Fermentation Processes for the Preparation of Tacrolimus
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
EP2604269B1 (fr) 2005-11-01 2014-09-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones possédant des propriétés thérapeutiques
EP1956906A4 (fr) 2005-11-09 2009-12-30 Combinatorx Inc Procedes, compositions et kits pour le traitement de pathologies
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
US7622477B2 (en) 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
DE602007006601D1 (de) * 2006-03-15 2010-07-01 Teva Gyogyszergyar Zartkoeruee Verfahren zur reinigung von tacrolimus
US8022188B2 (en) * 2006-04-24 2011-09-20 Abbott Laboratories Immunosuppressant binding antibodies and methods of obtaining and using same
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
CA2659549C (fr) 2006-06-09 2013-07-30 The Regents Of The University Of Michigan Compositions et procedes associes a de nouveaux composes et leurs cibles
EP2457589A1 (fr) 2006-08-31 2012-05-30 Astellas Pharma Inc. Ciblage inverse de vésicule de lipides
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
EP1960406A2 (fr) * 2006-11-06 2008-08-27 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Ascomycine et pimécrolimus ayant des niveaux réduits de desméthylascomycine et de 32-désoxy-32-épichloro-desméthylascomycine respectivement, et leurs procédés de préparation
EP2124898B1 (fr) 2007-01-10 2013-08-14 Board of Regents, The University of Texas System Administration amelioree de compositions medicamenteuses immunosuppressives par voie pulmonaire
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
US20100151436A1 (en) * 2007-03-02 2010-06-17 Fong Peter M Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
EP2139331B1 (fr) * 2007-03-09 2013-02-20 The Regents of the University of Michigan Compositions et procédés en rapport avec de nouveaux composés et cibles de ceux-ci
EP2167033B1 (fr) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Forme pharmaceutique orale à administrer une fois par jour comportant du tacrolimus
KR100891313B1 (ko) * 2007-08-17 2009-03-31 (주) 제노텍 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법
CN101855203B (zh) 2007-09-14 2014-03-19 密执安州立大学董事会 F1f0-atp合成酶抑制剂以及相关的方法
AU2008323945B2 (en) 2007-11-06 2013-11-28 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
CA2711765A1 (fr) * 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Animaux transgeniques de caspase dimerisable d'arret conditionnel
KR101003042B1 (ko) 2008-03-17 2010-12-21 종근당바이오 주식회사 고순도 타크로리무스의 정제 방법
EP2262892A4 (fr) * 2008-04-08 2011-09-21 Amyris Biotechnologies Inc Expression de séquences hétérologues
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010021681A2 (fr) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions et procédés pour le traitement de maladies virales
EP2352724B1 (fr) 2008-09-11 2015-04-22 The Regents of the University of Michigan Aryle guanidines comme inhibiteurs de la f1f0-atpase et leur utilisation medicale
KR100910165B1 (ko) 2008-09-18 2009-07-30 (주) 제노텍 은 이온 용액 추출을 이용한 불포화 알킬기를 가진 락톤 화합물 정제방법
CN102176913B (zh) * 2008-10-08 2014-08-13 高田制药株式会社 外用的他克莫司制剂
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
WO2010075549A2 (fr) 2008-12-23 2010-07-01 Pharmasset, Inc. Phosphoramidates de nucléosides
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
CN101712686B (zh) * 2009-06-22 2012-08-29 鲁南制药集团股份有限公司 一种发酵液中他克莫司的分离纯化方法
EP2272963A1 (fr) * 2009-07-09 2011-01-12 LEK Pharmaceuticals d.d. Procédé de préparation d'un tacrolimus
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
AU2010322287B2 (en) 2009-11-17 2014-04-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
CA2780333C (fr) 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones et composes apparentes presentant des proprietes therapeutiques
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US8480620B2 (en) 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US8951595B2 (en) 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
RS55118B1 (sr) 2010-02-17 2016-12-30 Veloxis Pharmaceuticals As Stabilizovana takrolimus kompozicija
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
US20110318277A1 (en) 2010-06-25 2011-12-29 APT Pharmaceuticals, Inc. University of Maryland, Baltimore Tacrolimus compositions for aerosol administration
KR101261131B1 (ko) 2010-08-24 2013-05-06 이화여자대학교 산학협력단 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주
MA34586B1 (fr) 2010-08-25 2013-10-02 Medis Lab Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees
US10117411B2 (en) 2010-10-06 2018-11-06 Dow Agrosciences Llc Maize cytoplasmic male sterility (CMS) C-type restorer RF4 gene, molecular markers and their use
CN106279401A (zh) 2011-03-11 2017-01-04 贝丝以色列女执事医疗中心 Cd40片段及其用途
WO2013163176A1 (fr) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticules pour le traitement d'allergies
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
UA116648C2 (uk) 2013-03-14 2018-04-25 Алкермес Фарма Айерленд Лімітед Фумарати як проліки та їх застосування при лікуванні різних захворювань
EP2981285B1 (fr) 2013-04-03 2020-06-03 N-Fold Llc Nouvelles compositions de nanoparticules
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN104650112B (zh) * 2013-11-18 2018-07-31 山东新时代药业有限公司 他克莫司8-丙基类似物的制备方法
UY35927A (es) 2013-12-31 2015-07-31 Dow Agrosciences Llc ?gen restaurador rf3 de tipo s de la esterilidad masculina citoplasmática del maíz (cms), marcadores moleculares y sus usos?.
WO2015106283A1 (fr) 2014-01-13 2015-07-16 Amplyx Pharmaceuticals, Inc. Composés antifongiques
EP3094314B1 (fr) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Nanosupports ciblés pour l'administration d'agents immunosuppresseurs
WO2015127450A1 (fr) 2014-02-24 2015-08-27 Alkermes Pharma Ireland Limited Sulfonamide et promédicaments de fumarates de sulfinamide et leur utilisation dans le traitement de diverses maladies
KR101694879B1 (ko) * 2014-08-01 2017-01-12 주식회사 인트론바이오테크놀로지 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도
WO2016068208A1 (fr) 2014-10-28 2016-05-06 国立研究開発法人国立成育医療研究センター Medicament pour ameliorer l'etat de grossesse, et son utilisation
MX2018001989A (es) 2015-08-19 2018-06-19 Vivus Inc Formulaciones farmaceuticas.
WO2017040932A1 (fr) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Anticorps humanisés anti-cd40 et leurs utilisations
CN106074367A (zh) * 2016-07-20 2016-11-09 中山大学中山眼科中心 含fk506类化合物/fkbp蛋白二聚体的药物组合物及其制备方法
CN108384819B (zh) * 2017-02-03 2021-06-25 上海医药工业研究院 一种用于发酵他克莫司的培养基以及发酵方法
RU2686779C1 (ru) * 2018-07-26 2019-04-30 Общество с ограниченной ответственностью "Изварино Фарма" Штамм streptomyces tsukubensis - продуцент такролимуса и способ получения такролимуса
AU2019318035A1 (en) 2018-08-10 2021-03-04 Koushi Yamaguchi Therapeutic agent for humoral immunity-related diseases in materno-fetal relationship
WO2020076738A2 (fr) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Composés à liaison protéinique
EP3930713A4 (fr) 2018-12-04 2022-11-16 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Formulation de pommade à base de tacrolimus stable pour le traitement topique d'affections cutanées
WO2020129348A1 (fr) 2018-12-18 2020-06-25 晃史 山口 Agent permettant de traiter l'infertilité, les fausses couches récurrentes et d'améliorer la grossesse
KR102135527B1 (ko) * 2018-12-18 2020-07-20 이문수 발가락 습기 제거 양말
GR1009790B (el) 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
IL305524A (en) 2021-03-03 2023-10-01 Sana Biotechnology Inc Immunosuppressive treatments for use with cardiomyocyte cell treatments, and associated methods and preparations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244592A (en) * 1962-06-09 1966-04-05 Arai Tadashi Ascomycin and process for its production
JPS54110000A (en) * 1978-02-17 1979-08-29 Kaken Pharmaceut Co Ltd Novel streptovaricin c derivative
US4309504A (en) * 1980-01-28 1982-01-05 Eli Lilly And Company Process for preparing narasin
US4654334A (en) * 1980-10-08 1987-03-31 International Minerals & Chemical Corp. Manganese-containing antibiotic agents
US4415669A (en) * 1981-12-07 1983-11-15 Merck & Co., Inc. Substance and process for its production
US4390546A (en) * 1981-12-07 1983-06-28 Merck & Co., Inc. Antiparasitic macrolide from a strain of Streptomyces hygroscopicus
US4510317A (en) * 1983-07-28 1985-04-09 Hoffmann-La Roche Inc. Antibiotic X-14934A
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
US5254562A (en) * 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5266692A (en) * 1984-12-03 1993-11-30 Fujisawa Pharmaceutical Co., Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CH677448A5 (fr) * 1987-11-09 1991-05-31 Sandoz Ag
US5956352A (en) * 1992-04-24 1999-09-21 Digital Equipment Corporation Adjustable filter for error detecting and correcting system

Also Published As

Publication number Publication date
KR930010706B1 (ko) 1993-11-08
FI864527A (fi) 1986-11-07
JP2828091B2 (ja) 1998-11-25
US5110811A (en) 1992-05-05
NO168372C (no) 1992-02-12
US4956352A (en) 1990-09-11
KR860004918A (ko) 1986-07-16
CY1912A (en) 1985-11-30
MX9202943A (es) 1992-06-30
ES8705038A1 (es) 1987-04-16
US5496727A (en) 1996-03-05
NZ214407A (en) 1989-11-28
US20030229115A1 (en) 2003-12-11
FI87803C (fi) 1993-02-25
JPH0346445B2 (fr) 1991-07-16
AU5059685A (en) 1986-06-12
DK556285A (da) 1986-06-04
HU195250B (en) 1988-04-28
JPH1067783A (ja) 1998-03-10
IL92345A (en) 1991-06-10
FI85977C (fi) 1992-06-25
HUT41842A (en) 1987-05-28
KR930010704B1 (ko) 1993-11-08
JP3211891B2 (ja) 2001-09-25
NO854833L (no) 1986-06-04
US6028097A (en) 2000-02-22
FI864527A0 (fi) 1986-11-07
JPH11343294A (ja) 1999-12-14
JPH0372484A (ja) 1991-03-27
US6482845B1 (en) 2002-11-19
US5830717A (en) 1998-11-03
DE3587806D1 (de) 1994-06-01
JP2746134B2 (ja) 1998-04-28
EP0184162B1 (fr) 1994-04-27
JPH07224066A (ja) 1995-08-22
FI87803B (fi) 1992-11-13
US4894366A (en) 1990-01-16
NL960023I1 (nl) 1996-12-02
HK18596A (en) 1996-02-09
KR930010705B1 (ko) 1993-11-08
NL960023I2 (nl) 1997-06-02
US5565559A (en) 1996-10-15
JPH0720970B2 (ja) 1995-03-08
AU592067B2 (en) 1990-01-04
US4929611A (en) 1990-05-29
JP2976966B2 (ja) 1999-11-10
DK556285D0 (da) 1985-11-29
DE19575026I2 (de) 2002-03-28
PT81589B (pt) 1987-10-20
KR930010708B1 (ko) 1993-11-08
FI854731A (fi) 1986-06-04
US20050124646A1 (en) 2005-06-09
PT81589A (en) 1986-01-01
FI85977B (fi) 1992-03-13
IE62865B1 (en) 1995-03-08
IE852971L (en) 1986-06-03
US5624842A (en) 1997-04-29
GR852904B (fr) 1986-04-01
CN1013687B (zh) 1991-08-28
US20030170831A1 (en) 2003-09-11
EP0184162A2 (fr) 1986-06-11
KR930010707B1 (ko) 1993-11-08
EP0184162A3 (en) 1989-02-08
CA1338491C (fr) 1996-07-30
ES549478A0 (es) 1987-04-16
JPH0372483A (ja) 1991-03-27
CN85109492A (zh) 1986-06-10
US6201005B1 (en) 2001-03-13
DE3587806T2 (de) 1994-08-25
JPH1112281A (ja) 1999-01-19
ATE104984T1 (de) 1994-05-15
US20040029908A1 (en) 2004-02-12
FI854731A0 (fi) 1985-11-29
IL77222A (en) 1991-06-10
NO168372B (no) 1991-11-04
DK169550B1 (da) 1994-11-28

Similar Documents

Publication Publication Date Title
LU90317I2 (fr) Tacrolimus et ses sels et dérivés pharmaceutiquement acceptables
NZ240676A (en) Heterocyclic compounds substituted by a (piperidin-4-yl)-1-oxoalkyl group and pharmaceutical compositions thereof
JPS56128767A (en) Substituted imidazole derivative, its manufacture and medicine as effective component
FR2401914A1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions medicinales contenant lesdits composes
HU9400250D0 (en) Quinoline-or quinazoine derivatives process fop producing them and pharmaceutical compositions containing them
ES8404361A1 (es) Un procedimiento para la preparacion de un derivado de cefalosporina.
JPS5665869A (en) Novel 22hydroxyalkyll3*4*55trihydroxyypiperidine compound* its manufacture and drug
SE8107273L (sv) 2-oxoazetidinderivat, sett att framstella democh anvendning derav
ATE48001T1 (de) Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate.
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
PT87277A (pt) Process for the preparation of new bicyclic compounds and pharmaceutical compositions comprising same
ES8403125A1 (es) Procedimiento para la preparacion de nuevas piridobenzodiazepinonas.
DK535384A (da) 1,3-dioxan-4-yl-alken- og alkansyrer, fremgangsmaader til fremstilling heraf og midler med indhold heraf
FR2396761A1 (fr) Procede de preparation du r,s-2,3,5,6-tetrahydro-6-phenyl-imidazo (2,1-b)-thiazole et de ses sels d'addition d'acide pharmaceutiquement acceptables, mettant en oeuvre un alkylxanthogenate ou du thiophene
FR2390956A1 (fr) Derives substitues de la quinolizidine et de l'indolizidine, leur procede de preparation et agents therapeutiques contenant lesdits derives
GB807618A (en) Improvements in or relating to therapeutically useful diamines